Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-02-21
2006-02-21
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S586000
Reexamination Certificate
active
07001898
ABSTRACT:
The invention is directed to nonpeptide substituted benzodiazepines of Formula I,wherein A, X, n, R1, R2, R3, R4, R5, a and b are as described in the specification, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention are also disclosed.
REFERENCES:
patent: 4617302 (1986-10-01), Robertson
patent: 5663431 (1997-09-01), Di Malta et al.
patent: 5686624 (1997-11-01), Di Malta et al.
patent: 5726322 (1998-03-01), Di Malta et al.
patent: 5728723 (1998-03-01), Di Malta et al.
patent: 5849780 (1998-12-01), Di Malta et al.
patent: 0 636 608 (1995-02-01), None
patent: 0 640 592 (1995-03-01), None
patent: WO 91 05549 (1991-05-01), None
patent: WO 94 07496 (1994-04-01), None
patent: WO 95 25443 (1995-09-01), None
patent: WO 97 49707 (1997-12-01), None
patent: WO 99 37637 (1999-07-01), None
M.A. Ashwell et al., “The Design, Synthesis and Physicochemical Properties of a Novel Series of Human Vasopressin V2Receptor Antagonists”, Wyeth-Ayerst Research, Princeton, New Jersey, 2000.
John P. Dusza et al., “Way-VNA-932: The First Orally Active, Nonpeptide, Vasopressin V2-Receptor Selective Agonist”, Wyeth-Ayerst Research, Princeton, New Jersey, date not available.
Jay S. Shumsky et al., “Pyridobenzodiazepines: Synthesis and Structure-Activity Relationships of a Novel Class of Orally Active Vasopressin V2Receptors”, Chemical Sciences Wyeth-Ayerst Research, Princeton, New Jersey, date not available.
Y. Shimada et al., “4,4-Difluoro-5-Methylene-2,3,4,5-Tetrahyro-1H-1-Benzazepine Derivatives: Highly Potent and Selective Antagonist of Arginine Vasopressin V1A Receptor”, Japan Pharmaceutical Co., Ltd., date not available.
Kazumi Kondo et al., “7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): A Potent, Orally Active Nonpeptide Arginine Vasopressin V2Receptor Antagonist”, Bioorganic & Medicinal Chemistry 7 (1999), pp. 1743-1754, Second Tokushima Institute of New Drug Research, Otsuka Pharmaceutical Co., Ltd., Japan.
Akira Matschisa et al., “Nonpeptide Arginine Vasopressin Antagonists for Both V1Aand V2Receptors: Synthesis and Pharmacological Properties of 4′-[5-(Substituted Methylidene)-2,3,4,5-tetrahydro-1H-1benzoazepine-1-carbonyl]benzanilide and 4′-[5-(Substituted Methyl)-2,3-dihydro-1H-1-benzoazepine-1-carbonyl]benzanilide Derivatives”, Pharamaceutical Society of Japan 1999, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Japan.
J. Donald Albright et al., “5-Fluoro-2-methyl-N-[4-(5H-pyrrolo2,1-c-1,4]benzodiazepin-10(11H)-ylcarbonyl)-3-Orally Active Arginine Vasopressin Antagonist with Selectivity for V2Receptors”, J. Med. Chem. 1998,41, pp. 2442-2444, American Chemical Society.
Kazumi Kondo et al., “Novel Design of Nonpeptide AVP V2Receptor Agonists: Structural Requirements for an Agonist Having 1-(4-Aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a Template”, J. Med. Chem., 2000, 43, pp. 4388-4397, American Chemical Society.
Takeyuki Yatsu et al., “Pharmacological profile of YM087, a novel nonpeptide dual vasopresin V1Aand V2receptor antagonists, in dogs”, European Journal of Pharmacology, 1997, 231, pp. 225-230, Elsevier Science B.V.
Yoshitaka Yamamura et al., “OPC-41061, a Highly Potent Human Vasopressin V2-Receptor Antagonist: Pharmacological Profile Aquaretic Effect by Single and Multiple Oral Dosing in Rats”, The Journal of Pharmacology and Experimental Therapeutics, 1998, vol. 287, No. 3, pp. 860-867, Second Tokushima Institute of New Drug Research et al., Japan.
Hariharan Venkatesan et al., Total Synthesis of SR 121463 A, a Highly Potent and Selective Vasopressin V2 Receptor Antagonist, The Journal of Organic Chemistry, 2001, vol. 66, No. 11, pp. 3653-3661, American Chemical Society.
PCT Search Report (PCT/US01/21080).
Chen Robert H. K.
Xiang Min A.
Lambkin Deborah C.
Ortho-McNeil Pharmaceutical , Inc.
Wright Sonya
LandOfFree
Nonpeptide substituted spirobenzoazepines as vasopressin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nonpeptide substituted spirobenzoazepines as vasopressin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nonpeptide substituted spirobenzoazepines as vasopressin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3682614